CA1214391A - Long-acting matrix tablet formulations - Google Patents
Long-acting matrix tablet formulationsInfo
- Publication number
- CA1214391A CA1214391A CA000434335A CA434335A CA1214391A CA 1214391 A CA1214391 A CA 1214391A CA 000434335 A CA000434335 A CA 000434335A CA 434335 A CA434335 A CA 434335A CA 1214391 A CA1214391 A CA 1214391A
- Authority
- CA
- Canada
- Prior art keywords
- tablet
- weight
- acid
- amount
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 116
- 238000009472 formulation Methods 0.000 title abstract description 15
- 239000013563 matrix tablet Substances 0.000 title abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 24
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 24
- 239000011159 matrix material Substances 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 77
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 52
- 239000001856 Ethyl cellulose Substances 0.000 claims description 27
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 27
- 229920001249 ethyl cellulose Polymers 0.000 claims description 27
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 26
- 229920002494 Zein Polymers 0.000 claims description 21
- 239000005019 zein Substances 0.000 claims description 21
- 229940093612 zein Drugs 0.000 claims description 21
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 20
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 19
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 17
- 239000004615 ingredient Substances 0.000 claims description 15
- YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical group N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 claims description 15
- 229960002906 trimazosin Drugs 0.000 claims description 15
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000003801 milling Methods 0.000 claims description 5
- 241001507939 Cormus domestica Species 0.000 claims description 2
- 239000003826 tablet Substances 0.000 abstract description 56
- 229920000642 polymer Polymers 0.000 abstract description 4
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 3
- 239000000194 fatty acid Substances 0.000 abstract description 3
- 229930195729 fatty acid Natural products 0.000 abstract description 3
- 150000004665 fatty acids Chemical class 0.000 abstract description 2
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 238000005469 granulation Methods 0.000 description 41
- 230000003179 granulation Effects 0.000 description 41
- 239000000378 calcium silicate Substances 0.000 description 30
- 229910052918 calcium silicate Inorganic materials 0.000 description 30
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 30
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
- 229960004667 ethyl cellulose Drugs 0.000 description 24
- 238000004090 dissolution Methods 0.000 description 15
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- 239000000463 material Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- -1 polyethylene Polymers 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000428 dust Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000009332 manuring Methods 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US407,511 | 1982-08-12 | ||
| US06/407,511 US4704284A (en) | 1982-08-12 | 1982-08-12 | Long-acting matrix tablet formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1214391A true CA1214391A (en) | 1986-11-25 |
Family
ID=23612384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000434335A Expired CA1214391A (en) | 1982-08-12 | 1983-08-10 | Long-acting matrix tablet formulations |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4704284A (forum.php) |
| EP (1) | EP0103387A3 (forum.php) |
| JP (1) | JPS5948415A (forum.php) |
| KR (1) | KR860000840B1 (forum.php) |
| AU (1) | AU546249B2 (forum.php) |
| CA (1) | CA1214391A (forum.php) |
| DK (1) | DK365883A (forum.php) |
| EG (1) | EG16065A (forum.php) |
| ES (1) | ES8502333A1 (forum.php) |
| FI (1) | FI82186C (forum.php) |
| GR (1) | GR78921B (forum.php) |
| GT (1) | GT198303076A (forum.php) |
| NO (1) | NO169818C (forum.php) |
| NZ (1) | NZ205205A (forum.php) |
| PH (1) | PH18211A (forum.php) |
| PT (1) | PT77185B (forum.php) |
| ZA (1) | ZA835900B (forum.php) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0729927B2 (ja) * | 1983-04-09 | 1995-04-05 | 日研化学株式会社 | テオフィリン徐放性製剤 |
| IE58246B1 (en) * | 1984-12-21 | 1993-08-11 | Byk Gulden Lomberg Chem Fab | Theophylline sustained release formulation |
| FR2585246A1 (fr) * | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
| US5188840A (en) * | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
| US4837032A (en) * | 1986-02-04 | 1989-06-06 | Farval Ag | Theophylline sustained release tablet |
| US4820523A (en) * | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
| JPH0776172B2 (ja) * | 1986-04-16 | 1995-08-16 | 藤沢薬品工業株式会社 | マトリツクス錠 |
| US4917892A (en) * | 1988-06-28 | 1990-04-17 | Temple University | Encapsulated topical delivery system |
| DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
| US5364646A (en) * | 1990-01-10 | 1994-11-15 | Dr. Karl Thomae Gmbh | Oral pharmaceutical forms of pimobendan |
| US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| MX9300110A (es) * | 1992-01-13 | 1994-07-29 | Gerhard Gergely | Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion. |
| US20070082918A1 (en) * | 1993-11-02 | 2007-04-12 | Naftchi N E | Neurologically active compounds and compounds with multiple activities |
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
| DE19631084A1 (de) * | 1996-08-01 | 1998-02-05 | Basf Ag | Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut |
| US6028929A (en) * | 1997-11-14 | 2000-02-22 | Tellabs Operations, Inc. | Echo canceller employing dual-H architecture having improved non-linear echo path detection |
| US20020106408A1 (en) * | 2000-12-01 | 2002-08-08 | Johnatan Bacon | Prolamin-based sustained-release compositions and delayed-onset compositions |
| RU2318518C2 (ru) * | 2002-02-26 | 2008-03-10 | Астразенека Аб | Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием |
| US20060093661A1 (en) * | 2002-05-07 | 2006-05-04 | Kapac, Llc | Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs |
| GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| ES2445947T3 (es) | 2003-08-13 | 2014-03-06 | Biocon Limited | Formulaciones para dosificación de sólidos de sales de ácidos grasos en forma de micropartículas para agentes terapéuticos |
| US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| WO2013135852A1 (en) | 2012-03-15 | 2013-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| MX373040B (es) | 2013-07-19 | 2020-05-26 | Boehringer Ingelheim Vetmedica Gmbh | Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador. |
| HUE032347T2 (en) | 2013-12-04 | 2017-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Pimobendan improved pharmaceuticals |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2793979A (en) * | 1953-03-30 | 1957-05-28 | Smith Kline French Lab | Method of making a sustained release pharmaceutical tablet and product of the method |
| US2953497A (en) * | 1953-06-03 | 1960-09-20 | Howard A Press | Therapeutic tablets |
| US3044938A (en) * | 1955-07-01 | 1962-07-17 | Sandoz Chemical Works Inc | Sustained action pharmaceutical tablets |
| US2809917A (en) * | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical tablets |
| BE564759A (forum.php) * | 1955-12-22 | |||
| US3039933A (en) * | 1957-10-07 | 1962-06-19 | Premo Pharmaceutical Lab Inc | Ethyl cellulose-polyethylene glycol tablet matrix |
| US2993836A (en) * | 1958-02-20 | 1961-07-25 | Dow Chemical Co | Sustained release tablets |
| US2956926A (en) * | 1958-09-23 | 1960-10-18 | American Cyanamid Co | Coated citric acid particles |
| US2987445A (en) * | 1958-10-10 | 1961-06-06 | Rohm & Haas | Drug composition |
| US3087860A (en) * | 1958-12-19 | 1963-04-30 | Abbott Lab | Method of prolonging release of drug from a precompressed solid carrier |
| US2951792A (en) * | 1959-11-18 | 1960-09-06 | Smith Kline French Lab | Sustained release pharmaceutical tablets |
| NL113366C (forum.php) * | 1961-02-24 | |||
| US3115441A (en) * | 1962-06-06 | 1963-12-24 | Victor M Hermelin | Timed release pharmaceutical preparations and method of making the same |
| US3336200A (en) * | 1963-05-28 | 1967-08-15 | Warner Lambert Pharmaceutical | Tablet structure |
| NL297631A (forum.php) * | 1963-06-03 | |||
| US3400197A (en) * | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
| FR1545612A (fr) * | 1967-06-15 | 1968-11-15 | Dausse Lab | Procédé de fabrication de comprimés |
| US3577514A (en) * | 1968-06-10 | 1971-05-04 | Pfizer | Sustained release pharmaceutical tablets |
| US3608063A (en) * | 1969-08-15 | 1971-09-21 | Gilbert S Banker | Molecular drug entrapment process and compositions |
| US3632739A (en) * | 1969-12-29 | 1972-01-04 | Sandoz Ag | Solid sustained release pharmaceutical preparation |
| US3669968A (en) * | 1970-05-21 | 1972-06-13 | Pfizer | Trialkoxy quinazolines |
| US3906086A (en) * | 1971-07-19 | 1975-09-16 | Richard G Powers | Timed-release aspirin |
| DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| US4012498A (en) * | 1974-03-27 | 1977-03-15 | Sandoz, Inc. | Sustained release tablet formulations |
| US3939259A (en) * | 1974-05-24 | 1976-02-17 | Anthony Pescetti | Coating composition and therapeutic preparation incorporating same |
| US3978203A (en) * | 1974-07-12 | 1976-08-31 | Dynatech Corporation | Sustained release of pharmaceuticals from polyester matrices |
| US4171363A (en) * | 1977-02-22 | 1979-10-16 | Bristol-Myers Company | 1,2,3-Thiadiazole process |
| US4122157A (en) * | 1977-03-04 | 1978-10-24 | Richardson-Merrell Inc. | Nitrofurantoin sustained release tablet |
| US4130647A (en) * | 1977-07-08 | 1978-12-19 | Pfizer Inc. | Methods for treating congestive heart failure and ischemic heart disease |
| DD146547A5 (de) * | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
| JPS55153715A (en) * | 1979-05-18 | 1980-11-29 | Nikken Kagaku Kk | Prolonged granule of theophylline |
| US4361545A (en) * | 1979-05-21 | 1982-11-30 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion |
| JPS5649314A (en) * | 1979-07-05 | 1981-05-02 | Yamanouchi Pharmaceut Co Ltd | Lasting pharmaceutical composition having prolonged action and its preparation |
| CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4248856A (en) * | 1979-07-10 | 1981-02-03 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| JPS56122311A (en) * | 1980-02-29 | 1981-09-25 | Eisai Co Ltd | Lasting theophylline pharmaceutical composition |
-
1982
- 1982-08-12 US US06/407,511 patent/US4704284A/en not_active Expired - Lifetime
-
1983
- 1983-08-03 EP EP83304478A patent/EP0103387A3/en not_active Ceased
- 1983-08-08 GR GR72161A patent/GR78921B/el unknown
- 1983-08-09 GT GT198303076A patent/GT198303076A/es unknown
- 1983-08-10 EG EG491/83A patent/EG16065A/xx active
- 1983-08-10 CA CA000434335A patent/CA1214391A/en not_active Expired
- 1983-08-10 PH PH29379A patent/PH18211A/en unknown
- 1983-08-10 JP JP58146293A patent/JPS5948415A/ja active Pending
- 1983-08-10 KR KR1019830003736A patent/KR860000840B1/ko not_active Expired
- 1983-08-10 NZ NZ205205A patent/NZ205205A/en unknown
- 1983-08-11 PT PT77185A patent/PT77185B/pt not_active IP Right Cessation
- 1983-08-11 AU AU17886/83A patent/AU546249B2/en not_active Ceased
- 1983-08-11 FI FI832895A patent/FI82186C/fi not_active IP Right Cessation
- 1983-08-11 NO NO832883A patent/NO169818C/no unknown
- 1983-08-11 DK DK365883A patent/DK365883A/da not_active Application Discontinuation
- 1983-08-11 ZA ZA835900A patent/ZA835900B/xx unknown
- 1983-08-11 ES ES524892A patent/ES8502333A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NZ205205A (en) | 1986-06-11 |
| EP0103387A2 (en) | 1984-03-21 |
| DK365883D0 (da) | 1983-08-11 |
| FI832895A0 (fi) | 1983-08-11 |
| EG16065A (en) | 1986-12-30 |
| FI82186B (fi) | 1990-10-31 |
| FI832895L (fi) | 1984-02-13 |
| GT198303076A (es) | 1985-01-30 |
| PT77185A (en) | 1983-09-01 |
| DK365883A (da) | 1984-02-13 |
| ZA835900B (en) | 1985-03-27 |
| NO169818C (no) | 1992-08-12 |
| ES524892A0 (es) | 1985-01-01 |
| ES8502333A1 (es) | 1985-01-01 |
| KR840005661A (ko) | 1984-11-15 |
| NO832883L (no) | 1984-02-13 |
| EP0103387A3 (en) | 1984-12-12 |
| US4704284A (en) | 1987-11-03 |
| FI82186C (fi) | 1991-02-11 |
| AU1788683A (en) | 1984-02-16 |
| GR78921B (forum.php) | 1984-10-02 |
| JPS5948415A (ja) | 1984-03-19 |
| PH18211A (en) | 1985-04-30 |
| PT77185B (en) | 1986-07-11 |
| AU546249B2 (en) | 1985-08-22 |
| NO169818B (no) | 1992-05-04 |
| KR860000840B1 (ko) | 1986-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1214391A (en) | Long-acting matrix tablet formulations | |
| US4765990A (en) | Sustained-release nifedipine preparation | |
| KR950007204B1 (ko) | 압축 성형 제제 | |
| CA1315202C (en) | Oral sustained release acetaminophen formulation and process | |
| EP0290168B1 (en) | Ibuprofen sustained release matrix and process | |
| US3965256A (en) | Slow release pharmaceutical compositions | |
| US4650664A (en) | Oral mopidamol preparation | |
| US4235870A (en) | Slow release pharmaceutical compositions | |
| US3344029A (en) | Sustained release composition | |
| CA2405031C (en) | Guaifenesin sustained release formulation and tablets | |
| US5030455A (en) | Sustained-release drug preparation | |
| IE57954B1 (en) | Storage-stable,quick disintegrating tablets | |
| EP0221732A2 (en) | Sustained release tablets | |
| AU2001255680A1 (en) | Guaifenesin sustained release formulation and tablets | |
| SI8710406A (en) | Sustained release tablets on the basis of high molecular weight hydroxypropylmethylcellulose and a process for their manufacture | |
| JPS625915A (ja) | 塩酸ジルチアゼム徐放性製剤及びその製法 | |
| JPH11286438A (ja) | 徐放性製剤 | |
| JP2521461B2 (ja) | 持続性錠剤 | |
| JPS61112012A (ja) | 持続放出性製剤の製造法 | |
| JPH09263537A (ja) | 徐放性塩酸ニカルジピン製剤 | |
| BG62234B1 (bg) | Фармацевтични състави,съдържащи гемфиброзил | |
| IE45283B1 (en) | Pharmaceutical formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |